X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Agamree (vamorolone) is a novel drug candidate with a mode of action based on binding to the mineralcorticosteroid receptor and modifying its downstream activity, being developed for the treatment Duchenne muscular dystrophy in 2 yaers and older patients.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: Agamree
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization.
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: DyDo Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Agamree (vamorolone) is a novel drug candidate candidate, which binds to the same receptor as corticosteroids but modifying its downstream activity and as such is considered a dissociative anti-inflammatory drug. Vamorolone is being indicated for DMD.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: Agamree
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2023
Details:
Firdapse (amifampridine) is approved for the treatment of Lambert-Eaton myasthenic syndrome and FDA recently accepted to review the Company's sNDA to increase the indicated maximum daily dosage of amifampridine tablets 10 mg from 80mg to 100mg.
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Details:
Under the agreement, Catalyst gains commercialization rights in North America for VBP15 (vamorolone), an investigational drug candidate with a mode of action based on binding to the same receptor as glucocorticoids, in Duchenne muscular dystrophy (DMD).
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: $231.0 million Upfront Cash: $75.0 million
Deal Type: Licensing Agreement July 19, 2023
Details:
Santhera will grant Catalyst exclusive commercialization rights to VBP15, an orally active dissociative steroidal anti-inflammatory agent, in North America and Santhera will continue to focus on European commercialization of vamorolone in duchenne muscular dystrophy.
Lead Product(s): Vamorolone
Therapeutic Area: Genetic Disease Product Name: VBP15
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Santhera Pharmaceuticals
Deal Size: $231.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement June 20, 2023
Details:
Firdapse (amifampridine) is a broad spectrum potassium channel blocker. sNDA submission has been planned to increase indicated maximum dose for firdapse® from 80 mg per day to 100 mg per day for the treatment of lambert eaton myasthenic syndrome ("LEMS").
Lead Product(s): Amifampridine
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
The completion of the acquisition, strengthens the company's Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy. Fycompa (perampanel), an oral medication, is a selective non-competitive AMPA receptor antagonist.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eisai
Deal Size: Undisclosed Upfront Cash: $160.0 million
Deal Type: Acquisition January 25, 2023
Details:
Firdapse (amifampridine phosphate) is a broad spectrum potassium channel blocker. Amifampridine is the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Lead Product(s): Amifampridine Phosphate
Therapeutic Area: Immunology Product Name: Firdapse
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
Fycompa (perampanel) is a non-competitive AMPA glutamate receptor antagonist used to treat partial-onset seizures with or without secondarily generalized seizures, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eisai
Deal Size: Undisclosed Upfront Cash: $160.0 million
Deal Type: Divestment December 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
